Latest Breaking News On - Ebopiprant rights - Page 1 : comparemela.com

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - December 1, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN) ("ObsEva" or the "Company"), a biopharmaceutical

Yuyuan bioscienceShauna dillonBrian ocallaghanExchange commissionManagement incKissei pharmaceutical co ltdChinese national medical products administrationSwiss exchangeBriano callaghanBusiness highlightsDrug evaluationChinese national medical productsEbopiprant rightsNasdaq stock marketThird quarter ended septemberOrganon license agreement